AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home iLIVER Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Application of biological big data and radiomics in hepatocellular carcinoma

Guoxu Fanga,b,1, Jianhui Fanc,1, Zongren Dinga,b,1, Yongyi Zenga( )
Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China
The Big Data Institute of Southeast Hepatobiliary Health Information, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China
Department of Hepatology for Pregnancy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China

1 These authors contributed equally to this work.

Show Author Information

Abstract

Hepatocellular carcinoma (HCC), one of the most common gastrointestinal cancers, has been considered a worldwide threat due to its high incidence and poor prognosis. In recent years, with the continuous emergence and promotion of new sequencing technologies in omics, genomics, transcriptomics, proteomics, and liquid biopsy are used to assess HCC heterogeneity from different perspectives and become a hotspot in the field of tumor precision medicine. In addition, with the continuous improvement of machine learning algorithms and deep learning algorithms, radiomics has made great progress in the field of ultrasound, CT and MRI for HCC. This article mainly reviews the research progress of biological big data and radiomics in HCC, and it provides new methods and ideas for the diagnosis, prognosis, and therapy of HCC.

Keywords

Hepatocellular carcinomaRadiomicsBiological big data

References

[1]

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68: 394–424.
Crossref Google Scholar
[2]

Suresh A, Dhanasekaran R. Implications of genetic heterogeneity in hepatocellular cancer. Adv Cancer Res 2022;156: 103–35.
Crossref Google Scholar
[3]

Sarveazad A, Agah S, Babahajian A, et al. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci 2019;24: 86.
Crossref Google Scholar
[4]

Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6.
Crossref Google Scholar
[5]

Ludwig DR, Fraum TJ, Cannella R, et al. Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria. HPB (Oxford) 2019;21: 1697–706.
Crossref Google Scholar
[6]

Nakamura I, Hatano E, Tada M, et al. Enhanced patterns on intraoperative contrast-enhanced ultrasonography predict outcomes after curative liver resection in patients with hepatocellular carcinoma. Surg Today 2021;51: 764–76.
Crossref Google Scholar
[7]

Avanzo M, Wei L, Stancanello J, et al. Machine and deep learning methods for radiomics. Med Phys 2020;47: e185–202.
Crossref Google Scholar
[8]

Harding-Theobald E, Louissaint J, Maraj B, et al. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther 2021;54: 890–901.
Crossref Google Scholar
[9]

Ahn SM, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 2014;60: 1972–82.
Crossref Google Scholar
[10]

Cancer Genome Atlas Research Network wbe. Electronic address, N. Cancer genome Atlas research, comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169: 1327–1341 e1323.
Crossref Google Scholar
[11]

Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44: 760–4.
Crossref Google Scholar
[12]

Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44: 694–8.
Crossref Google Scholar
[13]

Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reversetranscriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4: 2218.
Crossref Google Scholar
[14]

Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015;47: 505–11.
Crossref Google Scholar
[15]

Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014;46: 1267–73.
Crossref Google Scholar
[16]

Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 2014; 60: 1983–92.
Crossref Google Scholar
[17]

Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431–42.
Crossref Google Scholar
[18]

Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594–604.
Crossref Google Scholar
[19]

Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, et al. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS One 2012;7: e37707.
Crossref Google Scholar
[20]

Gouas DA, Villar S, Ortiz-Cuaran S, et al. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in the Gambia. Carcinogenesis 2012; 33: 1219–24.
Crossref Google Scholar
[21]

Wang H, Chen L, Zhou T, et al. p53 mutation at serine 249 and its gain of function are highly related to hepatocellular carcinoma after smoking exposure. Public Health Genomics 2021;24: 171–81.
Crossref Google Scholar
[22]

Lu LC, Shao YY, Lee YH, et al. beta-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma. Oncology 2014; 87: 159–66.
Crossref Google Scholar
[23]

Wang Z, Sheng YY, Gao XM, et al. beta-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol 2015;3: 936–40.
Crossref Google Scholar
[24]

Ding X, Yang Y, Han B, et al. Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS One 2014;9: e95307.
Crossref Google Scholar
[25]

Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res 2019;25: 2116–26.
Crossref Google Scholar
[26]

Ismail Labgaa AV. Liquid biopsy in liver cancer. Discov Med 2015;105: 263–73.
Google Scholar
[27]

Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012;72: 4875–82.
Crossref Google Scholar
[28]

Zhang Y, Liu Z, Ji K, et al. Clinical application value of circulating cell-free DNA in hepatocellular carcinoma. Front Mol Biosci 2021;8: 736330.
Crossref Google Scholar
[29]

Cai ZX, Chen G, Zeng YY, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma. Int J Cancer 2017;141: 977–85.
Crossref Google Scholar
[30]

Cox DR. Regression models and life-tables. J Roy Stat Soc Ser B (Methodological) 1972;34: 187–220.
Crossref Google Scholar
[31]

Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity 2020;52: 55–81.
Crossref Google Scholar
[32]

Melero I, Berman DM, Aznar MA, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015;15: 457–72.
Crossref Google Scholar
[33]

Huang R, Chen Z, Li W, et al. Immune system-associated genes increase malignant progression and can be used to predict clinical outcome in patients with hepatocellular carcinoma. Int J Oncol 2020;56: 1199–211.
Crossref Google Scholar
[34]

Li Y, He X, Zhang X, et al. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma. Life Sci 2021;265: 118799.
Crossref Google Scholar
[35]

Zhou P, Lu Y, Zhang Y, et al. Construction of an immune-related six-lncRNA signature to predict the outcomes, immune cell infiltration, and immunotherapy response in patients with hepatocellular carcinoma. Front Oncol 2021;11: 661758.
Crossref Google Scholar
[36]

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74.
Crossref Google Scholar
[37]

Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39: 126.
Crossref Google Scholar
[38]

Chen Z, Zou Y, Zhang Y, et al. A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma. J Clin Lab Anal 2021: e24005.
Crossref Google Scholar
[39]

Bai Y, Lin H, Chen J, et al. Identification of prognostic glycolysis-related lncRNA signature in tumor immune microenvironment of hepatocellular carcinoma. Front Mol Biosci 2021;8: 645084.
Crossref Google Scholar
[40]

Sangineto M, Villani R, Cavallone F, et al. Lipid metabolism in development and progression of hepatocellular carcinoma. Cancers (Basel) 2020;12.
Crossref Google Scholar
[41]

Wang W, Zhang C, Yu Q, et al. Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients. BMC Gastroenterol 2021;21: 68.
Crossref Google Scholar
[42]

Lee DY, Kim EH. Therapeutic effects of amino acids in liver diseases: current studies and future perspectives. J Cancer Prev 2019;24: 72–8.
Crossref Google Scholar
[43]

Tsun ZY, Possemato R. Amino acid management in cancer. Semin Cell Dev Biol 2015;43: 22–32.
Crossref Google Scholar
[44]

Lukey MJ, Katt WP, Cerione RA. Targeting amino acid metabolism for cancer therapy. Drug Discov Today 2017;22: 796–804.
Crossref Google Scholar
[45]

Dejong CHC, van de Poll MCG, Soeters PB, et al. Aromatic amino acid metabolism during liver failure. J Nutr 2007;137: 1579S–85S.
Crossref Google Scholar
[46]

Zhao Y, Zhang J, Wang S, et al. Identification and validation of a nine-gene amino acid metabolism-related risk signature in HCC. Front Cell Dev Biol 2021;9: 731790.
Crossref Google Scholar
[47]

Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death. Cell Death Differ 2018;25(2018): 486–541.
Crossref Google Scholar
[48]

Wu J, Wang Y, Jiang R, et al. Ferroptosis in liver disease: new insights into disease mechanisms. Cell Death Dis 2021;7: 276.
Crossref Google Scholar
[49]

Liang JY, Wang DS, Lin HC, et al. A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. Int J Biol Sci 2020;16: 2430–41.
Crossref Google Scholar
[50]

Xiong Y, Ouyang Y, Fang K, et al. Prediction of prognosis and molecular mechanism of ferroptosis in hepatocellular carcinoma based on bioinformatics methods. Comput Math Methods Med 2022;2022: 4558782.
Crossref Google Scholar
[51]

Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015;526: 660–5.
Crossref Google Scholar
[52]

Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for noncanonical inflammasome signalling. Nature 2015;526: 666–71.
Crossref Google Scholar
[53]

Julien O, Wells JA. Caspases and their substrates. Cell Death Differ 2017;24: 1380–9.
Crossref Google Scholar
[54]

Crawford ED, Wells JA. Caspase substrates and cellular remodeling. Annu Rev Biochem 2011;80: 1055–87.
Crossref Google Scholar
[55]

Zhang Z, Xia F, Xu Z, et al. Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma. Sci Rep 2022;12: 8886.
Crossref Google Scholar
[56]

Wu ZH, Li ZW, Yang DL, et al. Development and validation of a pyroptosis-related long non-coding RNA signature for hepatocellular carcinoma. Front Cell Dev Biol 2021;9: 713925.
Crossref Google Scholar
[57]

Wang Y, Kanneganti TD. From pyroptosis, apoptosis and necroptosis to PANoptosis: a mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J 2021;19: 4641–57.
Crossref Google Scholar
[58]

Scarpitta A, Hacker UT, Buning H, et al. Pyroptotic and necroptotic cell death in the tumor microenvironment and their potential to stimulate anti-tumor immune responses. Front Oncol 2021;11: 731598.
Crossref Google Scholar
[59]

Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damageassociated molecular patterns and its physiological relevance. Immunity 2013;38: 209–23.
Crossref Google Scholar
[60]

Liu L, Li H, Hu D, et al. Insights into N6-methyladenosine and programmed cell death in cancer. Mol Cancer 2022;21: 32.
Crossref Google Scholar
[61]

Meng T, Wang Q, Yang Y, et al. Construction of a necroptosis-related miRNA signature for predicting the prognosis of patients with hepatocellular carcinoma. Front Genet 2022;13: 825261.
Crossref Google Scholar
[62]

Chen C, Wu Y, Chen K, et al. Identification and validation of necroptosis-related LncRNA signature in hepatocellular carcinoma for prognosis estimation and microenvironment status. Front Genet 2022;13: 898507.
Crossref Google Scholar
[63]

Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer 2017;17: 528–42.
Crossref Google Scholar
[64]

Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov 2019;9: 1167–81.
Crossref Google Scholar
[65]

Huo X, Qi J, Huang K, et al. Identification of an autophagy-related gene signature that can improve prognosis of hepatocellular carcinoma patients. BMC Cancer 2020;20: 771.
Crossref Google Scholar
[66]

Wanli Yang LN, Zhao Xinhui, Duan Lili, et al. Development and validation of a survival model based on autophagy-associated genes for predicting prognosis of hepatocellular carcinoma. Am J Transl Res 2020;12: 6705–22.
Crossref Google Scholar
[67]

Yang S, Zhou Y, Zhang X, et al. The prognostic value of an autophagy-related lncRNA signature in hepatocellular carcinoma. BMC Bioinf 2021;22: 217.
Crossref Google Scholar
[68]

Nieto MA, Huang RY, Jackson RA, et al. Emt: 2016. Cell 2016;166(1): 21–45.
Crossref Google Scholar
[69]

Brabletz T. To differentiate or not–routes towards metastasis. Nat Rev Cancer 2012;12: 425–36.
Crossref Google Scholar
[70]

De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13: 97–110.
Crossref Google Scholar
[71]

Huang S, Li D, Zhuang L, et al. Identification of an epithelial-mesenchymal transition-related long non-coding RNA prognostic signature to determine the prognosis and drug treatment of hepatocellular carcinoma patients. Front Med (Lausanne) 2022;9: 850343.
Crossref Google Scholar
[72]

Xu BH, Jiang JH, Luo T, et al. Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma. Medicine (Baltimore) 2021;100: e26762.
Crossref Google Scholar
[73]

Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer 2019;18: 157.
Crossref Google Scholar
[74]

Zhou C, Zhang H, Lu L. Identification and validation of hypoxia-related lncRNA signature as a prognostic model for hepatocellular carcinoma. Front Genet 2021; 12: 744113.
Crossref Google Scholar
[75]

Tang P, Qu W, Wang T, et al. Identifying a hypoxia-related long non-coding RNAs signature to improve the prediction of prognosis and immunotherapy response in hepatocellular carcinoma. Front Genet 2021;12: 785185.
Crossref Google Scholar
[76]

Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 1998;19: 1853–61.
Crossref Google Scholar
[77]

Xing X, Liang D, Huang Y, et al. The application of proteomics in different aspects of hepatocellular carcinoma research. J Proteonomics 2016;145: 70–80.
Crossref Google Scholar
[78]

Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest 1956;8: 174.
Crossref Google Scholar
[79]

Hanif H, Ali MJ, Susheela AT, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022;28: 216–29.
Crossref Google Scholar
[80]

Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137: 110–8.
Crossref Google Scholar
[81]

Cheng J, Wang W, Zhang Y, et al. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS One 2014;9: e87011.
Crossref Google Scholar
[82]

Inagaki Y, Tang W, Makuuchi M, et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-gamma-carboxyprothrombin. Liver Int 2011;31: 22–35.
Crossref Google Scholar
[83]

Matsubara M, Shiraha H, Kataoka J, et al. Des-gamma-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27: 1602–8.
Crossref Google Scholar
[84]

Beale G, Chattopadhyay D, Gray J, et al. SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008;8: 200.
Crossref Google Scholar
[85]

Seo SI, Kim HS, Kim WJ, et al. Diagnostic value of PIVKA-Ⅱ and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2015;21: 3928–35.
Crossref Google Scholar
[86]

Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of desgamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101: 2038–43.
Crossref Google Scholar
[87]

Lee S, Rhim H, Kim YS, et al. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma. Liver Int 2016; 36: 580–7.
Crossref Google Scholar
[88]

Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55: 483–90.
Crossref Google Scholar
[89]

Qin L. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med 2014;8: 24–32.
Crossref Google Scholar
[90]

Zhu M, Zheng J, Wu F, et al. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. J Med Virol 2020;92: 3596–603.
Crossref Google Scholar
[91]

Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125: 89–97.
Crossref Google Scholar
[92]

Hey-Chi Hsu WC, Lai Po-Lin. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997;57: 5179–84.
Google Scholar
[93]

Zhou F, Shang W, Yu X, et al. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev 2018;38: 741–67.
Crossref Google Scholar
[94]

Lu Q, Li J, Cao H, et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep 2020;40.
Crossref Google Scholar
[95]

Bin Sun CH, Yang Zhibin, Zhang Xiaofeng, et al. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells. Oncotarget 2017;8: 32523–35.
Crossref Google Scholar
[96]

Pontisso P, Calabrese F, Benvegnu L, et al. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer 2004;90: 833–7.
Crossref Google Scholar
[97]

Chen H, Wong CC, Liu D, et al. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Theranostics 2019;9: 5246–60.
Crossref Google Scholar
[98]

Okoror LE, Ajayi AO, Ijalana OB. Elevated serum beta2-microglobulin in individuals coinfected with hepatitis B and hepatitis D virus in a rural settings in Southwest Nigeria. BMC Res Notes 2017;10: 719.
Crossref Google Scholar
[99]

Zhang R, Lin HM, Broering R, et al. Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the Wnt/beta-catenin signaling pathway. Signal Transduct Targeted Ther 2019;4: 54.
Crossref Google Scholar
[100]

Sun W, Zhang Y, Wong KC, et al. Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. Hepatology 2018;67: 2302–19.
Crossref Google Scholar
[101]

da Costa AN, Plymoth A, Santos-Silva D, et al. Osteopontin and latent-TGF beta binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer 2015;136: 172–81.
Crossref Google Scholar
[102]

Liu D, Wong CC, Fu L, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med 2018; 10(437): eaap9840.
Crossref Google Scholar
[103]

Korhani Kangi A, Bahrampour A. Predicting the survival of gastric cancer patients using artificial and bayesian neural networks. Asian Pac J Cancer Prev APJCP 2018;19: 487–90.
Google Scholar
[104]

Liu S, Wang Y, Yang X, et al. Deep learning in medical ultrasound analysis: a review. Engineering 2019;5: 261–75.
Crossref Google Scholar
[105]

Li W, Lv XZ, Zheng X, et al. Machine learning-based ultrasomics improves the diagnostic performance in differentiating focal nodular hyperplasia and atypical hepatocellular carcinoma. Front Oncol 2021;11: 544979.
Crossref Google Scholar
[106]

Yang Q, Wei J, Hao X, et al. Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: a multicentre study. EBioMedicine 2020;56: 102777.
Crossref Google Scholar
[107]

Kulkarni NM, Fung A, Kambadakone AR, et al. Computed tomography techniques, protocols, advancements, and future directions in liver diseases. Magn Reson Imag Clin N Am 2021;29: 305–20.
Crossref Google Scholar
[108]

Cao SE, Zhang LQ, Kuang SC, et al. Multiphase convolutional dense network for the classification of focal liver lesions on dynamic contrast-enhanced computed tomography. World J Gastroenterol 2020;26: 3660–72.
Crossref Google Scholar
[109]

Zhang H, Luo K, Deng R, et al. Deep learning-based CT imaging for the diagnosis of liver tumor. Comput Intell Neurosci 2022;2022: 3045370.
Crossref Google Scholar
[110]

Zhao C, Dai H, Shao J, et al. Accuracy of various forms of contrast-enhanced MRI for diagnosing hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol 2021;11: 680691.
Crossref Google Scholar
[111]

Wang SH, Han XJ, Du J, et al. Saliency-based 3D convolutional neural network for categorising common focal liver lesions on multisequence MRI. Insights Imaging 2021;12: 173.
Crossref Google Scholar
[112]

Liang W, Shao J, Liu W, et al. Differentiating hepatic epithelioid angiomyolipoma from hepatocellular carcinoma and focal nodular hyperplasia via radiomics models. Front Oncol 2020;10: 564307.
Crossref Google Scholar
[113]

Zhao X, Zhou Y, Zhang Y, et al. Radiomics based on contrast-enhanced MRI in differentiation between fat-poor angiomyolipoma and hepatocellular carcinoma in noncirrhotic liver: a multicenter analysis. Front Oncol 2021;11: 744756.
Crossref Google Scholar
[114]

Webster JD, Dunstan RW. Whole-slide imaging and automated image analysis: considerations and opportunities in the practice of pathology. Vet Pathol 2014;51: 211–23.
Crossref Google Scholar
[115]

Bera K, Schalper KA, Rimm DL, et al. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol 2019;16: 703–15.
Crossref Google Scholar
[116]

LeCun Y, Bengio Y, Hinton G. Deep learning. Nature 2015;521: 436–44.
Crossref Google Scholar
[117]

Cheng N, Ren Y, Zhou J, et al. Deep learning-based classification of hepatocellular nodular lesions on whole-slide histopathologic images. Gastroenterology 2022; 162: 1948–1961 e1947.
Crossref Google Scholar
[118]

Kiani A, Uyumazturk B, Rajpurkar P, et al. Impact of a deep learning assistant on the histopathologic classification of liver cancer. NPJ Digit Med 2020;3: 23.
Crossref Google Scholar
iLIVER
Volume 2 Issue 1,
March 2023
Pages 41-49
DOI: 10.1016/j.iliver.2023.01.003
Cite this article:
Fang G, Fan J, Ding Z, et al. Application of biological big data and radiomics in hepatocellular carcinoma. iLIVER, 2023, 2(1): 41-49. https://doi.org/10.1016/j.iliver.2023.01.003

433

Views

0

Crossref

Altmetrics
Received: 06 November 2022
Revised: 10 January 2023
Accepted: 27 January 2023
Published: 04 February 2023
© 2023 Published by Elsevier Ltd on behalf of Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return